By recapitulating the molecular and immune cell type heterogeneity characterizing HCC patients, the Alb-R26Met model exemplifies the heterogeneous vulnerability of tumor to distinct treatments, as illustrated here with their behavior as responding or non-responding subtypes following Decitabine or MEKi+BCL-XLi treatments. The gene discussed is ALB; the disease is hepatocellular carcinoma.